Reportable Segments (Tables)

12 Months Ended

Dec. 31, 2024

Reportable Segments

Schedule of segment profit or loss

	Year ended December 31,
(in thousands)	2024		2023		2022
Revenue:
Collaboration revenue	$	19,892	$	5,904	$	—
Operating expenses:
Personnel-related		31,569		50,910		45,158
Preclinical and manufacturing		13,645		21,574		16,511
Facilities-related		19,985		27,224		32,869
Stock-based compensation		14,609		24,341		24,452
Lab supplies		3,804		3,830		4,234
Consulting and professional services		10,648		10,719		11,966
Loss on lease termination		63,197		—		—
Other (1)		4,825		5,869		5,992
Total operating expenses		162,282		144,467		141,182
Loss from operations		(142,390)		(138,563)		(141,182)
Other income:
Other income and interest income, net		10,722		11,951		4,543
Net loss	$	(131,668)	$	(126,612)	$	(136,639)

(1) Other segment items include depreciation, amortization, license fees and other costs. Depreciation and amortization expense for the years ended December 31, 2024, 2023, and 2022 was $4.9 million, $5.3 million, and $5.1 million, respectively and are included in facilities-related and other segment operating expenses.